Basic and Clinical Neuroscience

Search published articles

Showing 2 results for Hasani Abharian

Short-term Efficacy of Commercial Curcumin Nanomicelle on Cognition, Oxidative Stress and Choline Esterase in AD's Disease

Dr Samira Kazemi, Dr Narges Hesni Langroudi, Dr Peyman Hasani Abharian, Prof Kamran Tavakol, Prof Mohammad Taghi Joghataei , Prof Shima Tavakol, Prof Sepide Arbabi Bidgoli,
Volume 0, Issue 0 (Accepted Articles 2018)

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease accompanied by cognitive dysfunction. Preclinical changes can precede the onset of clinical symptoms by a decade, highlighting the need for preventative and therapeutic strategies to mitigate or delay disease progression This pilot clinical trial, for the first time, investigated the effects of commercially available curcumin nanomicelles on oxidative stress pathways and serum cholinesterase levels in patients with AD. Fifteen volunteers with mild to severe AD and fifteen age-matched healthy controls were enrolled. Participants with AD received 80 mg of thermodynamically stable 10 nm curcumin nanomicelles on alternate days for two months. cognitive function, as assessed by the Mini-Mental State Examination (MMSE) , did not exhibit significant changes in AD patients following curcumin nanomicelle administration (19.8 versus 20.6). Serum levels of oxidative stress biomarkers, including catalase, superoxide dismutase (SOD) inhibition, malondialdehyde (MDA) concentration, and cholinesterase activity, were evaluated before and after intervention. The results showed no significant differences between the cognition improvement, catalase activity, SOD inhibition, MOD concentration, and cholinesterase activity between AD patients and healthy controls, or before and after curcumin nanomicelle administration. It might be concluded that although curcumin nanocarriers did not enhance antioxidant biomolecules, they did not provoke lipid peroxidation mechanisms. Therefore, the study suggests that optimization of nanocarrier parameters, including concentration, particle size larger than 10 nm, and blood-brain barrier targeting, warrants further investigation in a long-term study to explore their potential as a supplemental therapy for AD.

Effect of Transcranial Direct Current Stimulation on Dorsolateral Prefrontal Cortex to Reduce the Symptoms of the Obsessive-Compulsive Disorder

Sina Shafiezadeh, Mansoureh Eshghi, Zahra Dokhaei, Hossein Mohajeri, Atiyeh Mohammadshirazi, Sara Mirsadeghi, Peyman Hasani Abharian,
Volume 12, Issue 5 (September & October 2021)

Abstract

Introduction: Obsessive-Compulsive Disorder (OCD) is one of the most common debilitating mental disorders with a prevalence rate of 2% to 3% in the general population. Previous studies have indicated abnormalities in the dorsolateral prefrontal cortex (DLPFC) of OCD patients; thus, we decided to use transcranial Direct Current Stimulation (tDCS) to decline these patients’ symptoms.
Methods: A total of 24 patients with OCD participated in this study with the hope of improvement after the application of tDCS. The subjects were randomly assigned to three groups of Sham, Right DLPFC, and Left DLPFC. tDCS was applied for five consecutive days and in each session, patients were subjected to 2 mA current flow for two 15 minutes followed by a 10-minute rest in between (every session lasted for 40 minutes).
Results: Subsequently, the changes in obsessive-compulsive level and cognitive functions were evaluated via Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) and Depression, Anxiety, and Stress Scale 21 (DASS-21) by comparing the results before (pre-test) and after (post-test) tDCS treatment.
Conclusion: Ultimately, the scores of the Yale-Brown scale in the Left DLPFC group showed significant changes after treatment with tDCS (mean difference compared to the sham group: -6.18 and P≤0.05). Hereupon, this study demonstrated that transcranial direct current stimulation may cause improvements in symptoms of OCD.

Page 1 from 1

Designed & Developed by : Yektaweb